医学
癌胚抗原
胆囊癌
内科学
比例危险模型
肿瘤科
阶段(地层学)
危险系数
中性粒细胞与淋巴细胞比率
接收机工作特性
单变量分析
生物标志物
癌症
生存分析
胃肠病学
T级
多元分析
淋巴细胞
置信区间
古生物学
化学
生物
生物化学
作者
Xiwei Cui,Sha Zhu,Zhi‐Hang Tao,Xinghao Deng,Yexiao Wang,Yuanjing Gao,Yue Liao,Weijun Ma,Yiwen Zhang,Xuelei Ma
出处
期刊:Medicine
[Wolters Kluwer]
日期:2018-07-01
卷期号:97 (28): e11396-e11396
被引量:22
标识
DOI:10.1097/md.0000000000011396
摘要
Cancer-related inflammation and systemic inflammatory markers have been widely recognized as an essential part in tumor multiplication, invasion, and metastasis of tumor cells. This study aimed to estimate and compare the prognostic value of various biomarkers on overall survival (OS) in patients with gallbladder cancer patients.We performed a retrospective study of 159 patients received different therapies in West China Hospital from 2009 to 2014. The preoperative biomarker data, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), lactate dehydrogenase, and alkaline phosphatase, as well as other clinical information, were obtained from electronic record. And the receiver operating characteristic curves were used to analyze the optimal cut-off values of them. Kaplan-Meier survival analysis and Cox proportional hazard model analysis were applied to evaluate the association between markers and OS.The optimal cut-off value was 4.39 for NLR, 181.85 for PLR, 0.30 for MLR, and 3.02 for carcinoembryonic antigen (CEA). Kaplan-Meier analysis and univariate Cox analysis both demonstrated the significant prognostic value of NLR, MLR, and CEA. However, PLR failed to be a significant predictor of OS. The multivariate Cox analysis showed that preoperative NLR and CEA were independent prognostic factors for OS.Advanced tumor/node/metastasis stage, enhanced pretherapeutic NLR, and CEA were significantly associated with worse OS of gallbladder cancer patients. Furthermore, NLR was a better prognostic factor than CEA in advanced T (T3-T4) stage patients, while CEA was better for early T (T1-T2) stage, early N (N0-N1) stage, and early M (M0) stage patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI